tetano
Editor, Senior Moderator
Emerg Infect Dis. 2019 Feb;25(2). doi: 10.3201/eid2502.180359.
[h=1]Public Health-Driven Research and Innovation for Next-Generation Influenza Vaccines, European Union.[/h] Navarro-Torn? A, Hanrahan F, Kersti?ns B, Aguar P, Matthiessen L.
[h=3]Abstract[/h] Influenza virus infections are a major public health threat. Vaccination is available, but unpredictable antigenic changes in circulating strains require annual modification of seasonal influenza vaccines. Vaccine effectiveness has proven limited, particularly in certain groups, such as the elderly. Moreover, preparedness for upcoming pandemics is challenging because we can predict neither the strain that will cause the next pandemic nor the severity of the pandemic. The European Union fosters research and innovation to develop novel vaccines that evoke broadly protective and long-lasting immune responses against both seasonal and pandemic influenza, underpinned by a political commitment to global public health.
[h=4]KEYWORDS:[/h] European Union; biomedical research; drug legislation; financial support; global health; influenza; influenza pandemic; influenza vaccines; innovation; public health; vaccines; viruses
PMID: 30666948 DOI: 10.3201/eid2502.180359
Free full text
[TABLE="cellspacing: 1"]
[TR]
[TD="class: SL, width: 10%, align: right"][/TD]
[TD="class: SL, width: 20%, align: left"]Detect languageundefined[/TD]
[TD="class: SL, width: 3, align: center"]
[/TD]
[TD="class: SL, width: 20%, align: left"]undefined[/TD]
[TD="class: SL, width: 8%, align: center"]
[/TD]
[TD="class: SL, width: 8%, align: center"]
[/TD]
[TD="class: SL, width: 8%, align: center"]
[/TD]
[TD="class: SL, width: 8%, align: center"]
[/TD]
[TD="class: SL, width: 15%, align: right"]
[/TD]
[/TR]
[/TABLE]
Text-to-speech function is limited to 200 characters
[h=1]Public Health-Driven Research and Innovation for Next-Generation Influenza Vaccines, European Union.[/h] Navarro-Torn? A, Hanrahan F, Kersti?ns B, Aguar P, Matthiessen L.
[h=3]Abstract[/h] Influenza virus infections are a major public health threat. Vaccination is available, but unpredictable antigenic changes in circulating strains require annual modification of seasonal influenza vaccines. Vaccine effectiveness has proven limited, particularly in certain groups, such as the elderly. Moreover, preparedness for upcoming pandemics is challenging because we can predict neither the strain that will cause the next pandemic nor the severity of the pandemic. The European Union fosters research and innovation to develop novel vaccines that evoke broadly protective and long-lasting immune responses against both seasonal and pandemic influenza, underpinned by a political commitment to global public health.
[h=4]KEYWORDS:[/h] European Union; biomedical research; drug legislation; financial support; global health; influenza; influenza pandemic; influenza vaccines; innovation; public health; vaccines; viruses
PMID: 30666948 DOI: 10.3201/eid2502.180359
Free full text
[TABLE="cellspacing: 1"]
[TR]
[TD="class: SL, width: 10%, align: right"][/TD]
[TD="class: SL, width: 20%, align: left"]Detect languageundefined[/TD]
[TD="class: SL, width: 3, align: center"]
[/TD]
[TD="class: SL, width: 20%, align: left"]undefined[/TD]
[TD="class: SL, width: 8%, align: center"]
[/TD]
[TD="class: SL, width: 8%, align: center"]
[/TD]
[TD="class: SL, width: 8%, align: center"]
[/TD]
[TD="class: SL, width: 8%, align: center"]
[/TD]
[TD="class: SL, width: 15%, align: right"]
[/TD]
[/TR]
[/TABLE]
Text-to-speech function is limited to 200 characters